Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months in patients with optimal Pulsed Field Ablation applications First look results from admIRE study suggests similar outcomes Irvine, CA – February 2, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part […]
Rhythm
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., […]
GE HealthCare Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation
Latest digital platform provides key advancements to help maintain high signal fidelity while reducing environmental noise Forward-looking platform designed to help enable path to new technologies in the electrophysiology (EP) lab Chicago, IL – January 31, 2024 – GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka […]
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
HAYWARD, Calif.–(BUSINESS WIRE)– Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial fibrillation, today announced that its nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium in […]
Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator
SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the […]
ABBOTT ANNOUNCES FIRST GLOBAL PROCEDURES IN A CLINICAL TRIAL OF ITS VOLT™ PULSED FIELD ABLATION SYSTEM TO TREAT PATIENTS WITH ABNORMAL HEART RHYTHMS
ABBOTT PARK, Ill., Jan. 18, 2024 /PRNewswire/ — Abbott (NYSE: ABT) today announced the first global procedures have been conducted using the company’s new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib). Over 30 patients were recently treated in Australia as part of […]
PulseAI’s Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics
Innovative AI Application Improves Cardiac Monitoring and Diagnostic Accuracy BELFAST, Northern Ireland , Jan. 11, 2024 /PRNewswire/ — PulseAI, a leader in artificial intelligence healthcare solutions, today announced a significant advancement in consumer device electrocardiogram (ECG)…
Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan
First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world’s leading CARTO™ 3D cardiac mapping system for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib)…
Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter
ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC™. Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to […]
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute heart failure WARRINGTON, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology […]



